Prosecution Insights
Last updated: July 17, 2026
Application No. 17/795,515

Quinazoline compounds and the use thereof in the treatment of cancer

Non-Final OA §102
Filed
Jul 26, 2022
Priority
Feb 04, 2020 — AU 2020900302 +2 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Trobio Therapeutics Pty Ltd.
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
833 granted / 1122 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
59 currently pending
Career history
1176
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
23.4%
-16.6% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
51.0%
+11.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1122 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/10/2026 has been entered. Status of Claims Claims 1,11,13,18,38,47,56,61,66,78-80,83,87, and 91-93 are pending. Claims 47,56, 66,80,83,87, and 92 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1,11,13,18,38,61,78-79,91 and 93 is contained herein. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 3/26/2026 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 6/10/2026. New Objections and Rejections Claim Objections Applicant is advised that should claim 38 be found allowable, claim 78 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). In the instant case, the claims appear identical in scope. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1,11,13,18,38, 61, 78, 91, and 93 are rejected under 35 U.S.C. 102(a)(1) as being anticipated over PNG media_image1.png 14 268 media_image1.png Greyscale , PNG media_image2.png 18 232 media_image2.png Greyscale , and PNG media_image3.png 16 246 media_image3.png Greyscale in STNext. STNext teaches the following compound information: PNG media_image4.png 514 826 media_image4.png Greyscale PNG media_image5.png 436 776 media_image5.png Greyscale PNG media_image6.png 452 790 media_image6.png Greyscale wherein n = 0, 1, or 2, Y = alkoxy, X1 = 2 carbon alkyl group, and R2 = C3alkylOH. Thus the claims are anticipated. Conclusion Claims 1,11,13,18,38, 61, 78, 91, and 93 are rejected. Claim 79 is allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 26, 2022
Application Filed
Oct 21, 2025
Non-Final Rejection mailed — §102
Jan 08, 2026
Response Filed
Mar 26, 2026
Final Rejection mailed — §102
May 22, 2026
Response after Non-Final Action
Jun 10, 2026
Request for Continued Examination
Jun 11, 2026
Response after Non-Final Action
Jun 23, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673920
INHIBITORS OF NLRP3 INFLAMMASOME
3y 1m to grant Granted Jul 07, 2026
Patent 12667101
PICOLINAMIDE DERIVATIVES USEFUL AS AGRICULTURAL FUNGICIDES
4y 5m to grant Granted Jun 30, 2026
Patent 12668586
AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR
2y 3m to grant Granted Jun 30, 2026
Patent 12661362
Methods for the Prevention and Treatment of Hearing Loss
3y 6m to grant Granted Jun 23, 2026
Patent 12653804
USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS
5y 3m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.4%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1122 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month